Evidence map›Paper›PMID 41508550›Full record

Trial reportObesity (Silver Spring, Md.)2026

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.

Harold E Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06068946 (A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06068946 phase2completednot on this map

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

TypeinterventionalSponsorViking Therapeutics, Inc.Ran2023 to 2024Enrolled176ConditionsWeight LossArmsVK2735, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Future GLP-1 receptor co-agonists and their cardiac effects.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Review
  4. The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Harold E BaysLouisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, USA.ORCID https://orcid.org/0000-0001-9912-1408
Phillip TothMidwest Institute for Clinical Research, Indianapolis, Indiana, USA.
Naim AlkhouriSummit Clinical Research, San Antonio, Texas, USA.
John PullmanMercury Street Medical, Butte, Montana, USA.
Bradley FreilichKansas City Research Institute, Kansas City, Missouri, USA.
Joel NeutelOrange County Research Center, Lake Forest, California, USA.
Summer JiViking Therapeutics, Inc., San Diego, California, USA.
Scott StubbeViking Therapeutics, Inc., San Diego, California, USA.
Parke HedgesFlourish Research, San Antonio, Texas, USA.
Brian LianViking Therapeutics, Inc., San Diego, California, USA.

Funding

Viking Therapeutics, Inc.
6 · The paper itself

Abstract

objectiveThis study aimed to determine doses of VK2735, a novel glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.

methodsVENTURE was a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight-related comorbidity. Participants with diabetes mellitus were ineligible. The primary endpoint was percent change from baseline in body weight at Week 13. Secondary efficacy endpoints were observed and change from baseline weight loss and the proportion of participants losing ≥ 5% and ≥ 10% of baseline weight.

resultsStudy was conducted between August 2023 and February 2024. Mean weight reduction with active treatment ranged from 9.2 kg (2.5 mg dose) to 14.6 kg (15 mg dose), corresponding to 9.1% and 14.7% weight reductions, respectively; the placebo group had a 1.8 kg (1.7%) reduction. In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment. The common adverse events (AEs) were gastrointestinal, which decreased in reported frequency after dose titration to steady state.

conclusionsAll subcutaneous doses of VK2735 significantly reduced body weight. The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.

trial registrationClinicalTrials.gov identifier NCT06068946.

Indexed as

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsObesityReceptors, Gastrointestinal HormoneWeight LossAdultAgedDouble-Blind MethodFemaleGlucagon-Like Peptide-1 ReceptorHumansInjections, SubcutaneousMaleMiddle AgedOverweightTreatment OutcomeAnti-Obesity Agentsgastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Gastrointestinal HormoneantiobesityGLP‐1obesity treatmentweight lossweight management

Identifiers

PMID41508550
PMCPMC12933218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.